
@article{mayer_emtricitabine_2020,
	title = {Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for {HIV} pre-exposure prophylaxis ({DISCOVER}): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial},
	volume = {396},
	issn = {01406736},
	shorttitle = {Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for {HIV} pre-exposure prophylaxis ({DISCOVER})},
	url = {https://linkinghub.elsevier.com/retrieve/pii/S0140673620310655},
	doi = {10.1016/S0140-6736(20)31065-5},
	language = {en},
	number = {10246},
	urldate = {2025-12-28},
	journal = {The Lancet},
	author = {Mayer, Kenneth H and Molina, Jean-Michel and Thompson, Melanie A and Anderson, Peter L and Mounzer, Karam C and De Wet, Joss J and DeJesus, Edwin and Jessen, Heiko and Grant, Robert M and Ruane, Peter J and Wong, Pamela and Ebrahimi, Ramin and Zhong, Lijie and Mathias, Anita and Callebaut, Christian and Collins, Sean E and Das, Moupali and McCallister, Scott and Brainard, Diana M and Brinson, Cynthia and Clarke, Amanda and Coll, Pep and Post, Frank A and Hare, C Bradley},
	month = jul,
	year = {2020},
	pages = {239--254},
}
